PortfoliosLab logo
CSPC Pharmaceutical Group Ltd (1093.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

HK1093012172

IPO Date

Jun 21, 1994

Highlights

Market Cap

HK$65.54B

EPS (TTM)

HK$0.24

PE Ratio

14.35

PEG Ratio

7.60

Year Range

HK$4.27 - HK$7.62

Target Price

HK$6.81

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
1093.HK vs. DAX
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period

CSPC Pharmaceutical Group Ltd (1093.HK) returned 20.59% year-to-date (YTD) and -12.27% over the past 12 months. Over the past 10 years, 1093.HK returned -1.19% annually, underperforming the S&P 500 benchmark at 10.46%.


1093.HK

YTD

20.59%

1M

11.46%

6M

7.29%

1Y

-12.27%

5Y*

-16.39%

10Y*

-1.19%

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of 1093.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-6.09%5.37%4.88%24.09%-6.36%20.59%
2024-20.94%6.62%0.49%5.37%4.46%-6.18%-6.43%-17.18%25.52%-2.40%-11.83%-6.11%-31.26%
20239.02%-5.71%-8.42%3.37%-14.54%1.49%-4.70%-9.09%-0.32%18.99%3.22%2.98%-7.80%
202211.57%-2.12%-2.16%-10.50%5.02%-7.26%10.27%-6.99%-1.38%3.73%23.79%-17.92%-0.70%
2021-0.13%2.27%16.05%2.34%27.64%-7.72%-6.76%-5.82%-4.58%-12.85%-0.74%4.83%8.57%
2020-6.89%2.66%-12.61%-0.77%-1.43%-2.80%11.07%5.90%-12.68%-45.53%-7.34%4.76%-56.88%
201919.12%-0.45%8.96%3.56%-15.81%-0.32%9.21%13.95%0.38%28.02%-11.56%4.27%65.60%
201810.01%4.15%15.32%-3.12%21.92%-3.46%-13.50%-3.41%-16.06%-0.48%-4.23%-28.66%-28.16%
20175.80%8.45%7.16%6.09%8.54%-2.23%6.84%0.33%7.04%3.67%14.31%1.81%91.61%
2016-17.42%-5.35%13.41%-1.57%2.46%-1.74%-2.75%12.22%3.05%3.61%3.61%-0.60%5.40%
2015-4.24%-3.21%3.47%22.87%-0.35%-4.01%-7.31%0.00%-4.37%6.63%0.69%8.64%16.54%
20145.07%8.86%-1.86%-6.11%-4.67%1.31%-2.58%7.46%-0.77%11.04%-3.36%-0.87%12.48%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 1093.HK is 42, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 1093.HK is 4242
Overall Rank
The Sharpe Ratio Rank of 1093.HK is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of 1093.HK is 3939
Sortino Ratio Rank
The Omega Ratio Rank of 1093.HK is 3939
Omega Ratio Rank
The Calmar Ratio Rank of 1093.HK is 4545
Calmar Ratio Rank
The Martin Ratio Rank of 1093.HK is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for CSPC Pharmaceutical Group Ltd (1093.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

CSPC Pharmaceutical Group Ltd Sharpe ratios as of May 11, 2025 (values are recalculated daily):

  • 1-Year: -0.24
  • 5-Year: -0.36
  • 10-Year: -0.03
  • All Time: 0.14

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of CSPC Pharmaceutical Group Ltd compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History

CSPC Pharmaceutical Group Ltd provided a 5.23% dividend yield over the last twelve months, with an annual payout of HK$0.30 per share. The company has been increasing its dividends for 10 consecutive years.


0.00%1.00%2.00%3.00%4.00%5.00%6.00%HK$0.00HK$0.05HK$0.10HK$0.15HK$0.20HK$0.25HK$0.3020142015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020201920182017201620152014
DividendHK$0.30HK$0.30HK$0.25HK$0.20HK$0.17HK$0.16HK$0.09HK$0.08HK$0.06HK$0.06HK$0.05HK$0.04

Dividend yield

5.23%6.30%3.44%2.44%2.01%2.05%0.50%0.69%0.40%0.69%0.66%0.61%

Monthly Dividends

The table displays the monthly dividend distributions for CSPC Pharmaceutical Group Ltd. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.14HK$0.00HK$0.00HK$0.00HK$0.00HK$0.16HK$0.00HK$0.00HK$0.30
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.11HK$0.00HK$0.00HK$0.14HK$0.00HK$0.00HK$0.00HK$0.25
2022HK$0.00HK$0.00HK$0.00HK$0.00HK$0.10HK$0.00HK$0.00HK$0.00HK$0.10HK$0.00HK$0.00HK$0.00HK$0.20
2021HK$0.00HK$0.00HK$0.00HK$0.00HK$0.09HK$0.00HK$0.00HK$0.00HK$0.08HK$0.00HK$0.00HK$0.00HK$0.17
2020HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.13HK$0.00HK$0.00HK$0.04HK$0.00HK$0.00HK$0.00HK$0.16
2019HK$0.00HK$0.00HK$0.00HK$0.00HK$0.09HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.09
2018HK$0.00HK$0.00HK$0.00HK$0.00HK$0.08HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.08
2017HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06
2016HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.06
2015HK$0.00HK$0.00HK$0.00HK$0.00HK$0.05HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.05
2014HK$0.04HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.04

Dividend Yield & Payout


Dividend Yield

CSPC Pharmaceutical Group Ltd has a dividend yield of 5.23%, which is quite average when compared to the overall market.

Payout Ratio

CSPC Pharmaceutical Group Ltd has a payout ratio of 124.02%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the CSPC Pharmaceutical Group Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CSPC Pharmaceutical Group Ltd was 80.66%, occurring on Jan 15, 2025. The portfolio has not yet recovered.

The current CSPC Pharmaceutical Group Ltd drawdown is 74.43%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-80.66%Jun 6, 20181628Jan 15, 2025
-78.03%Apr 28, 2010522Jun 5, 2012386Dec 30, 2013908
-74.31%Jun 20, 2003738Jun 13, 2006235May 25, 2007973
-72.98%Oct 4, 2007260Oct 27, 2008213Sep 4, 2009473
-72.06%Sep 14, 1999495Sep 18, 2001331Jan 22, 2003826

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of CSPC Pharmaceutical Group Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of CSPC Pharmaceutical Group Ltd, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -14.1%.


0.050.100.150.2020212022202320242025
0.05
0.15
Actual
Estimate

Valuation

The Valuation section provides an overview of how CSPC Pharmaceutical Group Ltd is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for 1093.HK, comparing it with other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/E ratio of 14.4. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for 1093.HK compared to other companies in the Drug Manufacturers - General industry. 1093.HK currently has a PEG ratio of 7.6. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 1093.HK relative to other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 1093.HK in comparison with other companies in the Drug Manufacturers - General industry. Currently, 1093.HK has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items